You are here: Industry Insights > CLS-AX

News List

Clearside Biomedical Completes Dosing in First Cohort Trial of CLS-AX for Wet AMD americanpharmaceuticalreview
March 05, 2021
Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical Begins Enrollment for CLS-AX Trial for Wet AMD americanpharmaceuticalreview
January 20, 2021
Clearside Biomedical announced the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
Clearside Biomedical Announces FDA Acceptance of CLS-AX IND americanpharmaceuticalreview
August 14, 2020
Clearside Biomedical announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CLS-AX (axitinib injectable suspension) ...